摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴-N-甲基烟酰胺 | 869640-48-2

中文名称
6-溴-N-甲基烟酰胺
中文别名
——
英文名称
6-bromo-N-methylnicotinamide
英文别名
6-bromo-N-methylpyridine-3-carboxamide
6-溴-N-甲基烟酰胺化学式
CAS
869640-48-2
化学式
C7H7BrN2O
mdl
——
分子量
215.049
InChiKey
JHFJFJHQZAIQLE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    367.8±27.0 °C(Predicted)
  • 密度:
    1.545±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090
  • 储存条件:
    室温

SDS

SDS:a372d5784f1ea9bc2ffb4e335aaa9799
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 6-Bromo-N-methylnicotinamide
Synonyms: N-Methyl 6-bromonicotinamide; N-methyl 2-bromo-5-pyridinecarboxamide

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-N-methylnicotinamide
CAS number: 869640-48-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H7BrN2O
Molecular weight: 215.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    [FR] CERTAINS INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
    摘要:
    本文提供了某些化学实体。还提供了包括至少一种化学实体和一个或多个药用可接受载体的药物组合物。描述了治疗对KMO活性抑制敏感的某些疾病和紊乱的方法,包括向这些患者施用至少一种化学实体的有效量以减少疾病或紊乱的症状或体征。这些疾病包括亨廷顿病等神经退行性疾病。还描述了治疗方法,包括单独使用至少一种化学实体或将至少一种化学实体与一个或多个其他治疗药剂结合使用。还提供了筛选能够抑制KMO活性的化合物的方法。
    公开号:
    WO2011091153A1
  • 作为产物:
    描述:
    甲胺N,N'-羰基二咪唑 作用下, 以 二甲基亚砜四氢呋喃 为溶剂, 反应 42.0h, 以59%的产率得到6-溴-N-甲基烟酰胺
    参考文献:
    名称:
    EP1595881
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • HETEROBICYCLIC COMPOUNDS
    申请人:Amgen Inc.
    公开号:US20130225552A1
    公开(公告)日:2013-08-29
    Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.
    Formula (I)的杂环化合物: 或其药用可接受的盐、互变异构体或立体异构体,如规范中所定义,并含有它们的组合物,以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法,如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
  • [EN] 9H-PYRROLO-DIPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 9H-PYRROLO-DIPYRIDINE
    申请人:UCB BIOPHARMA SPRL
    公开号:WO2016124508A1
    公开(公告)日:2016-08-11
    The invention relates to 9H-pyrrolo-dipyridine derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection of Tau aggregates.
    这项发明涉及到式I的9H-吡咯-二吡啶衍生物,以及制备它们的方法、含有它们的药物组合物以及它们作为放射性药物的用途,特别是作为检测Tau聚集体的成像剂。
  • [EN] BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÈPINES COMME INHIBITEURS DE MTOR ET MÉTHODES D'UTILISATION ET DE FABRICATION
    申请人:EXELIXIS INC
    公开号:WO2010138490A1
    公开(公告)日:2010-12-02
    The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula wherein the combination of R1 and R2 are as defined herein, and pharmaceutically acceptable salts thereof.
    这项发明涉及 mTOR 的抑制剂及其药用盐或溶剂,以及它们的使用方法。这些抑制剂通常具有结构式,其中 R1 和 R2 的组合如本文所定义,并且其药用盐。
  • [EN] FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES<br/>[FR] DIHYDROPYRANNES FONDUS UTILISÉS COMME MODULATEURS DE GPR119 POUR TRAITER LE DIABÈTE, L'OBÉSITÉ ET LES MALADIES ASSOCIÉES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2012080476A1
    公开(公告)日:2012-06-21
    The present invention relates to compounds of general formula (I), wherein the groups R1, LP, LQ, X1, X2, X3, Ar and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
    本发明涉及一般式(I)的化合物,其中基团R1、LP、LQ、X1、X2、X3、Ar和n如申请中所定义,具有有价值的药理特性,特别是结合到GPR119受体并调节其活性。
  • Compounds, pharmaceutical compositions and uses thereof
    申请人:HIMMELSBACH Frank
    公开号:US20120322784A1
    公开(公告)日:2012-12-20
    The present invention relates to compounds of formula I, wherein the groups R 1 , L P , L Q , X 1 , X 2 , X 3 , Ar and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
    本发明涉及公式I的化合物, 其中R 1 ,LP,LQ,X 1 ,X 2 ,X 3 ,Ar和n的定义如申请中所述,具有有价值的药理特性,特别是结合GPR119受体并调节其活性。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-